Alkem Laboratories

3 weeks ago

Alkem Laboratories (ALKEM): Press Release

Press Release Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.". Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.".

Continue Reading

3 weeks ago

Alkem Laboratories First to Launch Semaglutide Pre-Filled Syringes in India

Alkem Laboratories has launched India's first semaglutide in single-shot pre-filled syringes, priced starting at INR 350 per dose, marking a significant advancement in accessible pharmaceutical formulations.

Continue Reading

3 weeks ago

Alkem Laboratories (ALKEM): Press Release

Press Release Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.". Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.".

Continue Reading

3 weeks ago

Alkem Laboratories (ALKEM): Press Release

Press Release Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.". Alkem Laboratories Limited has informed the Exchange regarding a press release dated Jun 02, 2026, titled "Alkem Laboratories Limited becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350.".

Continue Reading

3 weeks ago

Alkem Laboratories (ALKEM): Analysts/Institutional Investor Meet/Con. Call Updates

Analysts/Institutional Investor Meet/Con. Call Updates Alkem Laboratories Limited has informed the Exchange about Transcript Alkem Laboratories Limited has informed the Exchange about Transcript

Continue Reading

3 weeks ago

Alkem Laboratories (ALKEM): Analysts/Institutional Investor Meet/Con. Call Updates

Analysts/Institutional Investor Meet/Con. Call Updates Alkem Laboratories Limited has informed the Exchange about Transcript Alkem Laboratories Limited has informed the Exchange about Transcript

Continue Reading

3 weeks ago

Alkem Laboratories (ALKEM): Company Update

Company Update Please find Attached herewith Q4 FY26- Earnings Call Transcript. Please find Attached herewith Q4 FY26- Earnings Call Transcript.

Continue Reading

3 weeks ago

Alkem Laboratories (ALKEM): Company Update

Company Update Please find Attached herewith Q4 FY26- Earnings Call Transcript. Please find Attached herewith Q4 FY26- Earnings Call Transcript.

Continue Reading

3 weeks ago

Alkem Laboratories Shares Investor Presentation on NSE

Alkem Laboratories has filed its latest investor presentation with the NSE, giving market participants fresh insight into the company's business outlook and financial positioning.

Continue Reading

3 weeks ago

Alkem Laboratories Releases Q4 & FY26 Earnings Updates

Alkem Laboratories has released its Q4 and full-year FY2026 earnings materials through an official BSE filing, making the press release and analyst presentation accessible to investors.

Continue Reading

3 weeks ago

Alkem Laboratories Fixes Aug 7 Record Date for Final Dividend

Alkem Laboratories board has set August 7 as the record date for final dividend and August 20 as the AGM cut-off date, as disclosed in a BSE filing.

Continue Reading

3 weeks ago

Alkem Laboratories Board Recommends Rs 10 Final Dividend for FY25

Alkem Laboratories board has recommended a final dividend of Rs 10 per equity share for FY ended March 2025. The proposal awaits shareholder approval at the ensuing Annual General Meeting.

Continue Reading